The Dermatology Digest

JANUARY 15, 2024

Delgocitinib cream continues to perform well in chronic hand eczema (CHE) with limited systemic exposure, according to two studies presented at the 2024 Winter Clinical Dermatology Conference in Honolulu, Hawaii. This trial included samples from 313 people on active treatment.

Safety 36

Safety Eczema Dermatology Treatments 36

Dermatology Times

SEPTEMBER 25, 2023

Lilia Correa-Selm, MD, FAAD, FACMS, reviews the clinical trial data relating to the EVRIANCE study examining the use of vismodegib treatment in patients with locally advanced basal cell carcinoma, highlighting key efficacy and safety endpoints.

Safety 36

Safety Clinic Treatments 36

The Dermatology Digest

MAY 22, 2024

The first patient has been dosed in Zai Lab’s global Phase 2 clinical trial of ZL-1102, a topical anti-IL-17 investigational therapy for the treatment of mild to moderate chronic plaque psoriasis. ZL-1102 is the first IL-17 targeted topical treatment in development for patients with less severe forms of CPP.

Clinic 36

Clinic Therapy Safety Treatments 36

The Dermatology Digest

JULY 26, 2024

The CRL did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab. The post FDA Accepts BLA Resubmission of Cosibelimab for the Treatment of Advanced cSCC appeared first on The Dermatology Digest.

Treatments 36

Treatments Surgery Safety Clinic 36

Kim Gallo Esthetics

FEBRUARY 27, 2024

From basic skincare routines to targeted treatments and product recommendations, I’m here to provide you with expert advice that is both informative and educational. Emerging technology has afforded us the luxury of ingredients and treatments from around the globe, challenging us to balance traditional wisdom with progressive science.

Skincare 314

Skincare Esthetician Skincare Routine Chemical Peels 314

The Dermatology Digest

JUNE 10, 2024

Food and Drug Administration (FDA) approved Almirall’s recent supplemental New Drug Application (sNDA) to expand the use area of tirbanibulin ( Klisyri) for the treatment of actinic keratosis (AK) on the face or scalp up to 100 cm 2.

Treatments 36

Treatments Safety Office Clinic 36

The Dermatology Digest

APRIL 12, 2024

Recent cases where possibly counterfeit neurotoxins in Illinois and Tennessee led to a cluster of illnesses resembling Botulism highlight the need to strengthen patient safety through increased oversight of medical care in all settings, according to the American Society for Dermatologic Surgery Association (ASDSA).

Safety 69

Safety Surgery Medical Training 69

The Dermatology Digest

JUNE 5, 2024

Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. The randomized, double-blind, vehicle-controlled trial will evaluate the safety and efficacy of once-daily VYN201 topical gel in three dose cohorts (1%, 2% and 3% concentrations) compared to vehicle for 24 weeks.

Safety 73

Safety Office Facials Therapy 73

AAAMS

APRIL 17, 2024

Introduction to Aesthetic Treatments and Botox Aesthetic treatments have gained significant popularity in the realm of beauty and self-care. The growing demand for Botox treatments has increased the need for skilled professionals. It’s not just about looking younger but also feeling confident. What is Botox Certification?

Treatments 52

Treatments Injections Wrinkles Safety 52

The Dermatology Digest

MARCH 18, 2024

Food and Drug Administration (FDA) has accepted Journey Medical’s New Drug Application (NDA) for DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) for the treatment of inflammatory lesions and erythema of rosacea in adults. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of November 4, 2024. “We

Rosacea 74

Rosacea Medical Clinic Office 74

The Dermatology Digest

FEBRUARY 14, 2024

Food and Drug Administration (FDA) has accepted Galderma’s Biologics License Applications for nemolizumab for the treatment of patients with prurigo nodularis (PN) and for adolescents and adults with moderate to severe atopic dermatitis (AD). The FDA has granted nemolizumab Priority Review for prurigo nodularis.

Dermatitis 78

Dermatitis Clinic Safety Dermatology 78

Eminence Organics

FEBRUARY 27, 2024

Salt Saunas: Benefits Of Salt In Spa Treatments Think your spa has experienced every trend? Along with these newer therapies, we'll also discuss scientifically proven salt treatments, like salt scrubs, to give you a comprehensive view. Benefits | Scrubs & Other Salt Treatments | Can Everyone Enjoy Salt Treatments?

Treatments 59

Treatments Therapy Training Exfoliation 59

The Dermatology Digest

JULY 21, 2023

Pandya, MD, Director, Pigmentary Disorders Clinic, Palo Alto Foundation Medical Group, Sunnyvale, California; and Adjunct Professor of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas “This is the most exciting time of my career when it comes to treatment of vitiligo. 2020;396(10244):110-120.

Treatments 36

Treatments Safety Medical Clinic 36

Kim Gallo Esthetics

DECEMBER 23, 2022

A microcurrent facial is a treatment that uses low-level electrical currents to stimulate the muscles and the skin. Microcurrent facials are one of my favorite treatments to perform because they offer so many benefits for the skin! At Kim Gallo Esthetics, your comfort and safety is our top priority.

Facials 195

Facials Esthetics Skin Types Collagen 195

The Dermatology Digest

AUGUST 30, 2024

Merck is discontinuing the Phase 3 KEYNOTE-630 trial evaluating (pembrolizumab, Keytruda) for the adjuvant treatment of patients with high-risk locally advanced cutaneous squamous cell carcinoma (cSCC) following surgery and radiation, based on the recommendation of an independent Data Monitoring Committee (DMC).

Surgery 36

Surgery Safety Therapy Innovations 36

The Dermatology Digest

JULY 16, 2024

is starting its global Phase 3 program, consisting of two Phase 3 trials (EMBARQ-CSU1 and EMBARQ-CSU2) designed to establish the efficacy and safety of barzolvolimab in adult patients with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. Celldex Therapeutics, Inc.

Safety 36

Safety Clinic Dermatitis Dermatology 36

The Dermatology Digest

APRIL 4, 2024

Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for bimekizumab-bkzx (Bimzelx, UCB), an interleukin(IL)-17A and IL-17F inhibitor, for the treatment of adults with moderate-to-severe hidradenitis suppurativa (HS). at UCB in a news release. Bimzelx was approved in the U.S. In the U.S.,

Safety 57

Safety Injections Clinic Therapy 57

The Dermatology Digest

SEPTEMBER 12, 2024

In the confirmatory phase 3 study (LIBERTY-CUPID Study C), dupilumab met the primary and key secondary endpoints for the investigational treatment of patients with uncontrolled, biologic-naïve CSU receiving background therapy with antihistamines. At 24 weeks, efficacy among patients receiving Dupixent compared to placebo was as follows: 8.64-point

Safety 36

Safety Office Dermatology Medical 36

The Dermatology Digest

AUGUST 21, 2024

TMB-001 did not meet the primary and key secondary endpoints in a randomized, double-blind period of the phase 3 ASCEND clinical trial of congenital ichthyosis. The trial results do not support submission of a New Drug Application to the U.S. Food and Drug Administration, according to Leo Pharma and Timber Pharmaceuticals.

Pharmaceutical 36

Pharmaceutical Clinic Office Safety 36

Atelier Esthetique Institute of Esthetics

DECEMBER 5, 2023

Accrediting committees ensure that the quality and safety of your school is approved and noted by outside bodies. The Benefits of a Well-Rounded Curriculum If you’re going to esthetician school, you’ll want to know everything you can about the field, from skincare knowledge to the differences between treatments.

Esthetician 148

Esthetician Esthetics Education Training 148

New Age Spa Institute

APRIL 18, 2024

” Laser treatments for hair removal and skin rejuvenation are an often-connected part of the aesthetics industry, and there are some critical points to consider before pursuing a career in this field. This distinction is crucial for both practitioners and clients to understand, ensuring treatments are conducted safely and legally.

Legal 52

Legal Hair Removal Safety Esthetician 52

The Dermatology Digest

FEBRUARY 22, 2024

DermBiont has completed enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of seborrheic keratoses. “We We are pleased to have completed enrollment in our CT-213 clinical trial evaluating SM-020 gel 1.0% CEO, and Co-Founder of DermBiont, in a news release. or vehicle twice daily for 28 days.

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

FEBRUARY 22, 2024

DermBiont has completed enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of seborrheic keratoses. “We We are pleased to have completed enrollment in our CT-213 clinical trial evaluating SM-020 gel 1.0% CEO, and Co-Founder of DermBiont, in a news release. or vehicle twice daily for 28 days.

Safety 36

Safety Clinic Office Hyperpigmentation 36

The Dermatology Digest

AUGUST 14, 2024

s VP-315 is showing promise in the treatment of basal cell carcinoma, according to Part 2 of its Phase 2 clinical trial. Patients may be cured with simple injections of VP-315,” adds Jonathan Kantor, MD, a dermatologist and Mohs surgeon at Florida Center for Dermatology, which was the leading enrollment site for the clinical study.

Safety 36

Safety Pharmaceutical Clinic Dermatology 36

The Dermatology Digest

AUGUST 13, 2024

Food and Drug Administration (FDA) has approved nemolizumab (Nemluvio, Galderma) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis. Nemolizumab was generally well tolerated, and its safety profile was consistent with the phase II trial, and between the OLYMPIA 1 and 2 trials.

Dermatitis 36

Dermatitis Safety Clinic Dermatology 36

The Dermatology Digest

MAY 16, 2024

million, five-year National Institutes of Health (NIH) U01 grant to investigate dupilumab (Dupixent, Sanofi & Regeneron) as a treatment for children with alopecia areata. Current treatment options for alopecia areata harbor negative side effects for long-term use. Dr. Guttman. “If

Eczema 69

Eczema Dermatitis Safety Innovations 69

US Dermatologt Partners

JUNE 1, 2024

In the ever-evolving landscape of psoriasis treatment, oral therapies continue to play a crucial role. 1 In an interview with Dermatology Times, Lockshin explained how far we have come in oral treatment options for psoriasis, the future outlook, and patient populations that benefit most from orals. and a PASI 90 response rate of 22.3%.

Therapy 41

Therapy Injections Safety Management 41

AAFE - American Academy of Facial Esthetics

MARCH 28, 2024

However, a growing body of research and clinical practice has highlighted its potential benefits beyond mere aesthetic enhancement. This paper aims to delve into the long-term advantages of preventive Botox treatments, exploring its impact on aging, skin health, psychological well-being, and overall quality of life.

Wrinkles 60

Wrinkles Injections Skin Health Safety 60

The Dermatology Digest

AUGUST 15, 2024

DermBiont’s SM-020 is performing well in an ongoing open label, multi-center Phase 2a study for the treatment of basal cell carcinoma (BCC), the Company reports. The safety of the drug product is being evaluated based on frequency of adverse events (AEs) and application site reactions (ASRs). and CEO of DermBiont, in a news release.

Clinic 36

Clinic Scarring Office Safety 36

The Dermatology Digest

MARCH 5, 2024

FDA approval for the improvement of moderate to severe temple hollowing with results lasting up to 13 months with optimal treatment. ” In a study, more than 80% of subjects had at least a one-point improvement in moderate to severe temple hollowing three months after treatment, and the improvement lasted for more than one year (73%).

Portfolios 74

Portfolios Injections Training Facials 74

The Dermatology Digest

JANUARY 29, 2024

Food and Drug Administration (FDA) for treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older in December 2023. Zoryve foam was well-tolerated with a favorable safety and tolerability profile. There were no treatment-related Serious Adverse Events (SAEs). Zoryve foam was approved by the U.S.

Dermatitis 74

Dermatitis Safety Dermatology Treatments 74

First Derm

FEBRUARY 21, 2024

Social media significantly influences the popularity of retinol among young people, leading to increased experimentation without considering safety. There’s a crucial difference between cosmetic retinol use and medical treatment with retinoids ; the latter is for specific skin conditions under professional supervision.

Retinol 104

Retinol Social Media Skincare Routine Skincare 104

The Dermatology Digest

FEBRUARY 16, 2024

for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not adequately controlled with existing therapy. The safety profile of dupilumab in CSU was generally consistent with the known safety of Dupixent in its approved dermatological indications. and Novartis Pharmaceuticals).

Pharmaceutical 36

Pharmaceutical Safety Dermatitis Therapy 36

Dermatology Times

DECEMBER 21, 2023

Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices.

Safety 36

Safety Clinic Dermatology Treatments 36

The Dermatology Digest

MARCH 5, 2024

Food and Drug Administration (FDA) has given its nod to Letybo (foletibotulinumtoxinA) for the treatment of moderate-to-severe glabellar lines in adults. Now, there are six neuromodulators approved for cosmetic use in the U.S.: and Europe.

Branding 74

Branding Injections Safety Facials 74

The Dermatology Digest

MARCH 9, 2024

In the five JNJ-2113 treatment groups, as measured by the Psoriasis Area and Severity Index (PASI), response rates were maintained from Week 16 to Week 52, with the highest PASI 75 response observed in the 100 mg twice daily group (78.6 Across JNJ-2113 treatment groups, 58.6% at 16 weeks and 76.2 at 16 weeks and 64.3% at 52 weeks).

Sustainability 36

Sustainability Safety Dermatology Clinic 36

The Dermatology Digest

FEBRUARY 7, 2024

For the study, 255 participants were randomized into six treatment groups (placebo [n=43], 25 mg daily [n=43], 25 mg twice-daily [n=41], 50 mg daily [n=43], 100 mg daily [n=43], and 100 mg twice-daily [n=42]). Lower levels of hBD-2 were observed with clinical response and indicate inhibition of the IL-17/IL-23 axis.

Safety 36

Safety Clinic Office Dermatology 36